SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-006124
Filing Date
2020-05-11
Accepted
2020-05-11 08:21:12
Documents
55
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ruby-20200331x10q.htm 10-Q 1885005
2 EX-10.1 ruby-20200331ex101fc6ccb.htm EX-10.1 153710
3 EX-10.2 ruby-20200331ex102203b18.htm EX-10.2 151175
4 EX-31.1 ruby-20200331ex311c1c3d1.htm EX-31.1 13633
5 EX-31.2 ruby-20200331ex312d82397.htm EX-31.2 12849
6 EX-32.1 ruby-20200331ex3212ddbbf.htm EX-32.1 8102
7 EX-32.2 ruby-20200331ex322d9624c.htm EX-32.2 8083
  Complete submission text file 0001558370-20-006124.txt   5324477

Data Files

Seq Description Document Type Size
8 EX-101.INS ruby-20200331.xml EX-101.INS 846136
9 EX-101.SCH ruby-20200331.xsd EX-101.SCH 30733
10 EX-101.CAL ruby-20200331_cal.xml EX-101.CAL 38598
11 EX-101.DEF ruby-20200331_def.xml EX-101.DEF 97667
12 EX-101.LAB ruby-20200331_lab.xml EX-101.LAB 319320
13 EX-101.PRE ruby-20200331_pre.xml EX-101.PRE 214706
Mailing Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139
Business Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139 617-679-9600
Rubius Therapeutics, Inc. (Filer) CIK: 0001709401 (see all company filings)

IRS No.: 042688109 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38586 | Film No.: 20862725
SIC: 2836 Biological Products, (No Diagnostic Substances)